Literature DB >> 29191440

Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study.

Kelsey B Loeliger1, Frederick L Altice2, Mayur M Desai3, Maria M Ciarleglio4, Colleen Gallagher5, Jaimie P Meyer6.   

Abstract

BACKGROUND: Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services.
METHODS: To create a retrospective cohort of all adults with HIV released from jails and prisons in Connecticut, USA (2007-14), we linked administrative custody and pharmacy databases with mandatory HIV/AIDS surveillance monitoring and case management data. We examined time to LTC (defined as first viral load measurement after release) and viral suppression at LTC. We used generalised estimating equations to show predictors of LTC within 14 days and 30 days of release.
FINDINGS: Among 3302 incarceration periods for 1350 individuals between 2007 and 2014, 672 (21%) of 3181 periods had LTC within 14 days of release, 1042 (34%) of 3064 had LTC within 30 days of release, and 301 (29%) of 1042 had detectable viral loads at LTC. Factors positively associated with LTC within 14 days of release are intermediate (31-364 days) incarceration duration (adjusted odds ratio 1·52; 95% CI 1·19-1·95), and transitional case management (1·65; 1·36-1·99), receipt of antiretroviral therapy during incarceration (1·39; 1·11-1·74), and two or more medical comorbidities (1·86; 1·48-2·36). Reincarceration (0·70; 0·56-0·88) and conditional release (0·62; 0·50-0·78) were negatively associated with LTC within 14 days. Hispanic ethnicity, bonded release, and psychiatric comorbidity were also associated with LTC within 30 days but reincarceration was not.
INTERPRETATION: LTC after release is suboptimal but improves when inmates' medical, psychiatric, and case management needs are identified and addressed before release. People who are rapidly cycling through jail facilities are particularly vulnerable to missed linkage opportunities. The use of integrated programmes to align justice and health-care goals has great potential to improve long-term HIV treatment outcomes. FUNDING: US National Institutes of Health.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29191440      PMCID: PMC5807129          DOI: 10.1016/S2352-3018(17)30209-6

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  26 in total

1.  Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.

Authors:  Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

2.  All-cause, drug-related, and HIV-related mortality risk by trajectories of jail incarceration and homelessness among adults in New York City.

Authors:  Sungwoo Lim; Tiffany G Harris; Denis Nash; Mary Clare Lennon; Lorna E Thorpe
Journal:  Am J Epidemiol       Date:  2015-02-05       Impact factor: 4.897

3.  Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.

Authors:  M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

4.  Enrollment in outpatient care among newly released prison inmates with HIV infection.

Authors:  Jacques G Baillargeon; Thomas P Giordano; Amy Jo Harzke; Gwen Baillargeon; Josiah D Rich; David P Paar
Journal:  Public Health Rep       Date:  2010 Jan-Feb       Impact factor: 2.792

5.  HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.

Authors:  Jaimie P Meyer; Javier Cepeda; Sandra A Springer; Johnny Wu; Robert L Trestman; Frederick L Altice
Journal:  Lancet HIV       Date:  2014-11-01       Impact factor: 12.767

6.  Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention.

Authors:  M-J Milloy; Julio S G Montaner; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

7.  Positive Transitions (POST): Evaluation of an HIV Prevention Intervention for HIV-Positive Persons Releasing from Correctional Facilities.

Authors:  Robin J MacGowan; Julie Lifshay; Yuko Mizuno; Wayne D Johnson; Lyle McCormick; Barry Zack
Journal:  AIDS Behav       Date:  2015-06

8.  Accessing antiretroviral therapy following release from prison.

Authors:  Jacques Baillargeon; Thomas P Giordano; Josiah D Rich; Z Helen Wu; Katherine Wells; Brad H Pollock; David P Paar
Journal:  JAMA       Date:  2009-02-25       Impact factor: 56.272

9.  The impact of antiretroviral therapy in a cohort of HIV infected patients going in and out of the San Francisco county jail.

Authors:  Nitika Pant Pai; Milton Estes; Erica E M Moodie; Arthur L Reingold; Jacqueline P Tulsky
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

10.  Multilevel challenges to engagement in HIV care after prison release: a theory-informed qualitative study comparing prisoners' perspectives before and after community reentry.

Authors:  Danielle F Haley; Carol E Golin; Claire E Farel; David A Wohl; Anna M Scheyett; Jenna J Garrett; David L Rosen; Sharon D Parker
Journal:  BMC Public Health       Date:  2014-12-09       Impact factor: 3.295

View more
  29 in total

1.  Antiretroviral Adherence Following Prison Release in a Randomized Trial of the imPACT Intervention to Maintain Suppression of HIV Viremia.

Authors:  Bethany L DiPrete; Brian W Pence; Carol E Golin; Kevin Knight; Patrick M Flynn; Jessica Carda-Auten; Jennifer S Groves; Kimberly A Powers; Becky L White; Sonia Napravnik; David A Wohl
Journal:  AIDS Behav       Date:  2019-09

2.  Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.

Authors:  Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

3.  Adherence to Antiretroviral Therapy Among Incarcerated Persons with HIV: Associations with Methadone and Perceived Safety.

Authors:  Gabriel J Culbert; Agung Waluyo; Melinda Wang; Tissa Aulia Putri; Alexander R Bazazi; Frederick L Altice
Journal:  AIDS Behav       Date:  2019-08

4.  The Influence of Housing Status on the HIV Continuum of Care: Results From a Multisite Study of Patient Navigation Models to Build a Medical Home for People Living With HIV Experiencing Homelessness.

Authors:  Serena Rajabiun; Janell Tryon; Matt Feaster; Amy Pan; Lisa McKeithan; Karen Fortu; Howard J Cabral; Deborah Borne; Frederick L Altice
Journal:  Am J Public Health       Date:  2018-12       Impact factor: 9.308

5.  Health Care-Specific Enacted HIV-Related Stigma's Association with Antiretroviral Therapy Adherence and Viral Suppression Among People Living with HIV in Florida.

Authors:  Angel B Algarin; Diana M Sheehan; Nelson Varas-Diaz; Kristopher P Fennie; Zhi Zhou; Emma C Spencer; Robert L Cook; Jamie P Morano; Gladys E Ibanez
Journal:  AIDS Patient Care STDS       Date:  2020-07       Impact factor: 5.078

Review 6.  Prisons: ignore them at our peril.

Authors:  Adeeba Kamarulzaman; Annette Verster; Frederick L Altice
Journal:  Curr Opin HIV AIDS       Date:  2019-09       Impact factor: 4.283

7.  Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia.

Authors:  Divya K Chandra; Alexander R Bazazi; Muzammil A Nahaboo Solim; Adeeba Kamarulzaman; Frederick L Altice; Gabriel J Culbert
Journal:  HIV Res Clin Pract       Date:  2019-05-01

Review 8.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Authors:  Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

9.  Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine.

Authors:  Julia Rozanova; Olga Morozova; Lyuba Azbel; Chethan Bachireddy; Jacob M Izenberg; Tetiana Kiriazova; Sergiy Dvoryak; Frederick L Altice
Journal:  J Urban Health       Date:  2018-08       Impact factor: 3.671

10.  Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Authors:  Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.